Biomarkers From the Microbiome to Predict ALD Progression and Its Severity: A Comprehensive Review

Area of Science:

• Hepatology
• Microbiology
• Gastroenterology

Background:

• Alcohol consumption is a leading global health concern, contributing to millions of deaths annually.
• Alcohol-associated liver disease (ALD) progresses through distinct stages, from fatty liver to cancer, with early intervention crucial for reversal.
• Current diagnostic methods for ALD lack the sensitivity and specificity needed for early detection and accurate staging.

Purpose of the Study:

• To review the alterations in gut microbiota composition at various stages of ALD.
• To evaluate the diagnostic and prognostic potential of gut microbiota-associated biomarkers, including microbial metabolites.
• To discuss the limitations of current biomarkers and the emerging role of microbiome-derived signals in understanding ALD mechanisms.

Main Methods:

• Systematic review of existing literature on gut microbiota in alcohol-associated liver disease.
• Analysis of studies focusing on microbial metabolites and other microbiome-derived signals as biomarkers.
• Evaluation of the diagnostic and prognostic utility of identified biomarkers.

Main Results:

• Significant alterations in gut microbiota occur across the spectrum of alcohol-associated liver disease.
• Microbial metabolites and other microbiome-derived signals show potential as novel biomarkers for ALD diagnosis and staging.
• Existing biomarkers for ALD are limited in sensitivity and specificity for early disease detection.

Conclusions:

• Gut microbiota-related biomarkers represent a promising, albeit evolving, approach for improving early detection of ALD.
• Understanding microbiome-derived signals can enhance the mechanistic insight into ALD progression.
• Further research is needed to validate and implement these novel biomarkers in clinical practice for ALD management.